AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT03514836
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: immunomodulatory medication given around the ONCOS-102 dosing
Trial: NCT02253459
Drug: UTD1 Injection plus capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02253459
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01230827
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
Trial: NCT01230827
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
Trial: NCT00879333
Drug: Best Supportive Care (BSC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
Trial: NCT03571230
Drug: one proton pump inhibitor(PPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All the patients need this drug.
Trial: NCT02430298
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
Trial: NCT02430298
Drug: Matched Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
Trial: NCT01521494
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04418908
Drug: Estradiol Patch, 0.025 Mg/24 Hours Weekly Transdermal Film, Extended Release
RxNorm normalized name: Estradiol Patch, 0.025 mg/24 hours weekly transdermal film, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active estradiol transdermal patch.
Trial: NCT04418908
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patch designed to match active Climara patches.
Trial: NCT00882440
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsule to losartan
Trial: NCT04683627
Drug: Diclofenac sodium active topical patch
RxNorm normalized name: diclofenac sodium Medicated Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A topical patch with diclofenac sodium as active ingredient was used and evaluated for the treatment of OA pain of the knee.
Trial: NCT04683627
Drug: Placebo patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo patch without diclofenac sodium was used for the placebo arm.
Trial: NCT00424463
Drug: MCI-186
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
Trial: NCT03396900
Drug: RhBMP-2 Protein, Recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone morphogenetic proteins (BMPs) are a category of proteins that are involved in bone formation and repair. Among these, BMP-2 is one of the most potent members of the BMP family and has been used for correcting intrabony, supraalveolar, furcation, and fenestration defects due to its osteoinductive property. BMP's are also essential for differentiation of osteoclasts, but their role in this process remains unclear. Treatment of osteoclasts with exogenous BMP-2 directly enhances RANKL-stimulated differentiation of osteoclast precursors in vitro and stimulates survival and resorptive activity of mature osteoclasts that accelerates the tooth movement.
Trial: NCT04649541
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% dextrose in water
Trial: NCT04218266
Drug: BAY2433334
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, taken orally once a day.
Trial: NCT01935622
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxycycline 1 tablet every 12 hours for 14 days
Trial: NCT01935622
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 1 tablet every 12 hours for 14 days
Trial: NCT01927640
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline infusion (10 cc)
Trial: NCT03524846
Drug: Ascorbic Acid 300 MG
RxNorm normalized name: ascorbic acid 300 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 300 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Trial: NCT03435666
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single oral dose (1250mg/m2) Capecitabine or XELODA in each period.
Trial: NCT03524846
Drug: Ascorbic Acid 600 MG
RxNorm normalized name: ascorbic acid 600 MG
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid 600 mg was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Trial: NCT03524846
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline was administered intravenously for 5 minutes after each dialysis session, three times per week for 12 weeks.
Trial: NCT03852602
Drug: Preemptive Analgesics
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesic application15 minutes before the treatment
Trial: NCT00570089
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
Trial: NCT00002494
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01351103
Drug: LGK974
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002494
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002494
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002494
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002494
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02592031
Drug: XM17
RxNorm normalized name: Ximelagatran
DrugBank: Ximelagatran (DB04898)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Trial: NCT01749930
Drug: BOL-303259-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
Trial: NCT02592031
Drug: Gonal-f®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Trial: NCT02592031
Drug: Zoladex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.6 mg
Trial: NCT01749930
Drug: BOL-303259-X
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
Trial: NCT01327924
Drug: Norditropin NordiFlex®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
Trial: NCT02057939
Drug: Androgen Deprivation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
Trial: NCT02709850
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9%NaCl, water, riboflavin
Trial: NCT00510406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT01872078
Drug: AZD4901 (oral)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
Trial: NCT04377308
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine 20 mg to 60 mg daily given from 2 weeks to 2 months duration
Trial: NCT00600639
Drug: standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
Trial: NCT00600639
Drug: standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxygen plus medical therapy for ARF
Trial: NCT02119650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg matching placebo tablets to be administered by mouth
Trial: NCT04497766
Drug: Nebulized Magnesium sulfate
RxNorm normalized name: Hydra-Neb
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MgSO4 100mg in 20 ml normal saline will be given via ultrasonic nebulizer over 10 minutes,and PAS score will be assessed at 30,60,120,240,360 minutes
Trial: NCT04497766
Drug: Intravenous magnesium sulphate
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: pts age 2 to 12 years will receive intravenous magnesium sulphate 50 mg/kg over half hour
Trial: NCT02824458
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03770689
Drug: Peposertib 50 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received peposertib 50 milligram (mg) once daily 5 days per week up to 5.5 weeks.
Trial: NCT03770689
Drug: Peposertib 100 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received peposertib 100 mg once daily 5 days per week up to 5.5 weeks.
Trial: NCT03770689
Drug: Peposertib 150 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received peposertib 150 mg once daily 5 days per week up to 5.5 weeks.
Trial: NCT03770689
Drug: Peposertib 250 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received peposertib 250 mg once daily 5 days per week up to 5.5 weeks.
Trial: NCT03770689
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants received capecitabine at a dose of 825 milligram per square meter (mg/m\^2) twice daily 5 days per week up to 5.5 weeks.
Trial: NCT02269475
Drug: MEDI3250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEDI3250
Trial: NCT02269475
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT04758416
Drug: 68Ga-HER2 affibody,18F-FDG, 18F-FES
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 68Ga-NOTA-MAL-MZHER2 (68Ga-HER2) affibody is an investigational Positron Emission Tomography (PET)/ Computed Tomography (CT) radiopharmaceutical.
Trial: NCT03387670
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: * One (1 = 40mg) simvastatin tablet once daily at night for 1 month~* Two (2 = 80mg) simvastatin tablets once daily at night, for the next 35 to 53 months
Trial: NCT03387670
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * One (1) placebo tablet once daily at night for 1 month~* Two (2) placebo tablets once daily at night, for the next 35 to 53 months
Trial: NCT03040999
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline or dextrose solution administered as an IV infusion Q3W
Trial: NCT01901809
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02253914
Drug: BILR 355 BS, solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02253914
Drug: BILR 355 BS, tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00645034
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo by mouth as a single dose
Trial: NCT03428230
Drug: 60 mg Paracetamol 3% (2 mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Trial: NCT02253914
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03428230
Drug: 90 mg Paracetamol 3% (3 mL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Paracetamol followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Paracetamol will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Trial: NCT00435409
Drug: Sunitinib + Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.~Capecitabine administered orally at a starting dose of 2000 mg/m\^2 per day \[1000 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons.
Trial: NCT00435409
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine administered orally at a starting dose of 2500 mg/m\^2 per day \[1250 mg/m\^2 bid (twice daily)\] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
Trial: NCT04474470
Drug: NT219
RxNorm normalized name: NT219
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of NT219 as a single agent in adult subjects with recurrent and/or metastatic solid tumors
Trial: NCT04474470
Drug: NT219 and ERBITUX® - Dose Escalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of NT219 in combination with standard dose ERBITUX® in adult subjects with recurrent and/or metastatic squamous cell carcinoma of the head and neck and colorectal adenocarcinoma
Trial: NCT04474470
Drug: NT219 and ERBITUX® - Expansion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expansion cohort of NT219 at its RP2D in combination with standard dose ERBITUX® in adult patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck
Trial: NCT02113267
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
Trial: NCT03428230
Drug: Placebo, 0.9% saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single administration by intrathecal injection just before spinal anaesthesia. The injections will be performed according to the hospital procedures. For the intrathecal injection of Placebo followed by the intrathecal injection of the anaesthetic, two needles will be used: one introducer needle, which will serve to introduce the second needle through the skin, plus one intrathecal Pencil point needle (27-G or 25-Gauge or Reganesth or Nizell needle) to which the first syringe containing Placebo will be attached first, followed by the second syringe with the anaesthetic. In this way only one intrathecal puncture will be performed. Lumbar puncture will be done according to the standard hospital procedures.
Trial: NCT01279668
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablets, once per day for 28 days.
Trial: NCT00903162
Drug: zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: If desired, given intravenously every 6 months for a total of 4 injections (optional)
Trial: NCT01091168
Drug: Alkylating agent of physician choice registered in cancer
RxNorm normalized name: petroleum alkylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
Trial: NCT00199082
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00199082
Drug: Dexamethasone/Prednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00199082
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01865474
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 DLBS1033 tablet 490 mg thrice daily for 2 months
Trial: NCT01865474
Drug: placebo tablet of DLBS1033
RxNorm normalized name: PLACEBO TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 placebo tablet of DLBS1033 thrice daily for 2 months
Trial: NCT03582215
Drug: Part 1: Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Trial: NCT03582215
Drug: Part 1: Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Trial: NCT03582215
Drug: Part 1: Spray 1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Trial: NCT03582215
Drug: Part 1: Spray 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 4 times per day for 4 days to approximately 75% of the body surface area
Trial: NCT01060410
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous injection, 0.2g, once every two days
Trial: NCT00812461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: as-needed use, tablets, orally, 6 months
Trial: NCT03342079
Drug: Local Anesthetics,(lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical anesthetic (lidocaine 70 mg/tetracaine 70 mg topical patch; Synera)
Trial: NCT03342079
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo topical anesthetic
Trial: NCT00041119
Drug: AC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00041119
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00041119
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT03582215
Drug: Part 2: Lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Trial: NCT03582215
Drug: Part 2: Aerosol Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area
Trial: NCT03582215
Drug: Part 2: Nonaerosol Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 2 mg per cm2 of body surface will be applied topically 1 time on day 1 and 4 times per day on following 3 days to approximately 75% of the body surface area